%0 Journal Article %J Central European Journal of Immunology %@ 1426-3912 %V 45 %N 2 %D 2020 %F Yalcin2020 %T Human(ized) monoclonal antibodies in atopic patients – state of the art %X Asthma is an important chronic disease affecting a lot of people worldwide. Treatment options for asthma like biological agents are being developed more frequently nowadays. Despite a lot of treatment options, some patients still remain symptomatic. As more and more practitioners choose treatment with biologic agents as a convenient way of therapy, biologic agents and other valuable methods must be discovered in order to cope with a growing number of treatment agents. This manuscript emphasizes on new generation monoclonal human(ized) antibodies in asthmatics and off-label use . The first developed biologic agent is the anti-immunoglobulin E monoclonal antibody called omalizumab. Currently it is an approved treatment option for asthma. %A Yalcin, Arzu Didem %A Onbasi, Kevser %A Uzun, Rusen %A Herth, Felix %A Schnabel, Philipp Albert %P 195-201 %9 journal article %R 10.5114/ceji.2020.97909 %U http://dx.doi.org/10.5114/ceji.2020.97909